In-vivo study of Naltrexone hydrochloride (cas 16676-29-2) release from an in-situ forming PLGA-PEG-PLGA system in the rabbit

Add time:09/06/2019    Source:sciencedirect.com

A thermosensitive hydrogel of PLGA-PEG-PLGA triblock synthesized via ring opening polymerization using microwave irradiation method was used to control the release of naltrexone HCl drug. In the present work, the injectable prepared hydrogel was dissolved in phosphate buffer with different amounts of Naltrexone hydrochloride (cas 16676-29-2). The pharmacokinetic profiles of the drug in rabbits were determined using blood and urine samples after subcutaneous injection of drug formulations (naltrexone hydrochloride solution or naltrexone hydrochloride-hydrogel with doses of 5 and 15 mg/kg body weight). The concentrations of naltrexone HCl and its main metabolite (beta-naltrexol) were determined using a calibrated HPLC analytical method. The samples were collected and analyzed for 14 days. The serum concentrations of naltrexone HCl and β-naltrexol were significantly higher in drug-loaded hydrogels, compared to free injected naltrexone. This phenomenon is attributed to an effective accumulation of naltrexone HCl serum concentration during the process of slow release from hydrogel form (i.e. that amount of newly released naltrexone from hydrogel form, was added to that amount of metabolized drug released previously). As a conclusion, PLGA-PEG-PLGA copolymer can be evaluated as a biodegradable controlled release drug delivery system for naltrexone hydrochloride in the future human studies.

We also recommend Trading Suppliers and Manufacturers of Naltrexone hydrochloride (cas 16676-29-2). Pls Click Website Link as below: cas 16676-29-2 suppliers

Prev:FT-IR, FT-Raman and NMR characterization of 2-isopropyl-5-methylcyclohexyl quinoline-2-carboxylate and investigation of its reactive and optoelectronic properties by molecular dynamics simulations and DFT calculations
Next:Pharmaceutics, Preformulation and Drug DeliveryDesign and Evaluation of Controlled-Release Niosomes and Discomes for Naltrexone hydrochloride (cas 16676-29-2) Ocular Delivery)